We feature an interview of the selected supplier in our monthly customer newsletter, on our blog and social media. Below is this month's Spotlight on Cancer Genetics, Inc. (CGI, Nasdaq: CGIX) – a leader in enabling precision medicine for oncology from bench to bedside through the use of oncology biomarkers and molecular testing.
What is your company’s mission?
CGI’s mission is to empower personalized cancer treatment around the globe by developing and delivering products and services that drive the highest levels of patient value for optimal patient care management. CGI's innovative products and services are poised to transform cancer patient management, increase treatment efficacy, and reduce healthcare costs.
Describe your company’s most popular service offering.
Disease-specific, next-generation sequencing assays for heme and solid tumor indications.
Why should customers use your services?
Do you save time, money or provide access to innovation?
CGI’s research focuses on the development of state-of-the-art applications for the detection of genomic abnormalities in cancer and offers these applications to physicians and Biopharma clients for patient care and clinical trial programs.
CGI has a corporate culture that inspires innovation, respects knowledge and fosters leadership. CGI has a dedicated staff that takes pride in our specialized and streamlined laboratory services, superior turnaround time (TAT), enhanced reporting, EMR integration, and ongoing research and development for new innovative tests.
What new services, tools or technologies will you be offering over the next biennium?
Multi-analyte protein immunofluorescence for FFPE, additional flow-based assays for heme indications, additional ctDNA assays, additional rare cell (CTC) genomic and pharmacodynamic assays, and translational solutions including access to services for primary cell line development for downstream drug resistance/sensitivity experiments and genomic studies.
What is your company doing to remain an industry leader?
CGI has established strong research collaborations with key thought leaders in oncology and major cancer centers within the U.S. and abroad. These collaborations enable us to develop and validate new innovative proprietary tests in a clinical setting with the gained access to robust patient data. CGI’s abundant knowledge in oncology and vast testing capabilities allows for these proprietary tests to be tailored to the collaborators’ needs and specifications and to offer these tests to physicians and biopharma for use in the clinical and trial settings. CGI also scans the new technology landscape and adopts.
Have you been able to use Scientist.com to increase your business?
Scientist.com has enabled CGI to establish new client relationships and to expand a few current relationships. CGI supports this eCommerce model since it facilitates the ability of academics and pharma to more effectively mine for the needed tools and technology and expedites research and development more effectively. CGI is very aware of the benefit of Scientist.com's centralized services agreement model, which have a cost-benefit advantage for biopharma and CGI by reducing time and costs for legal review of individual MSAs and associated SOWs.
Guru is currently Director of Scientific Content at Scientist.com, the world’s largest pharmaceutical marketplace for scientific services. He is responsible for ensuring that Scientist.com includes the latest tools and technologies. Prior to Scientist.com, Guru helped launch several life science startups and a non-profit cancer foundation.